HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Matthew Powell, MD, and Floor Backes, MD, enthusiastically discuss the practice-changing RUBY trial results presented at the 2023 ESMO Congress showing impressive survival benefits with immunotherapy plus chemotherapy for both MMR-deficient and MMR-proficient advanced endometrial cancer.
Explore the case of a 67-year-old patient with recurrent endometrial cancer, highlighting the importance of MMR testing, NGS, and emerging treatment options in today's landscape.
ESMO: PARP inhibitor plus immunotherapy lowers risk of endometrial cancer progression over chemotherapy alone medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca: IMFINZI (durvalumab) plus LYNPARZA (olaparib) reduced the risk of disease progression or death by 45% vs chemotherapy in advanced or recurrent endometrial cancer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.